Why the study?
Does SC-52012, a peptide mimetic of the RGDF sequence, potently inhibit platelet aggregation in preclinical models?
Does SC-52012, a peptide mimetic of the RGDF sequence, potently inhibit platelet aggregation in preclinical models?
Peptide mimetics of the RGDF sequence with benzamidine replacement demonstrate potent inhibition of platelet aggregation via the GP IIb-IIIa receptor in preclinical models.
Answers are grounded in this paper and cite their sources.
High-potency platelet inhibition in dogs supports RGDF mimetic advancement; leaves open clinical translation and safety in humans.
Peptide mimetics of the RGDF sequence in which Arg-Gly has been replaced with 5-(4-amidinophenyl)pentanoyl mimetic has led to a 1000-fold increase in inhibitory potency over the natural RGDF ligand. The guanidine residue of the arginine may be involved in a reinforced ionic interaction with a carboxylate of the receptor which could explain the dramatic increase in potency upon replacement with benzamidine. This hypothesis is supported by the observation of low inhibitory potency of the corresponding benzylamine (18) and no activity with the corresponding imidazoline derivative (19); plus, ab initio calculations on the respective complexes suggest that the benzamidine-carboxylate is more favorable than the guanidine-carboxylate interaction. The ED50 for the inhibition of ex vivo collagen induced platelet aggregation in the dog for SC-52012 (1) was 0.32 microgram/kg/min by iv infusion with a pharmacodynamic half-life for recovery of approximately 40 min.
No takes yet. Share an insight, caveat, or question.
Zablocki et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: